Stock Rating Downgrade
In the last week the Value Trend Rating for Corcept Therapeutics Inc (NASDAQ: CORT) weakened from B to C reflecting eroding fundamentals and low Appreciation Potential.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock suffered a major decline of -19.5% on 4/1/25. The shares closed at $91.93. Moreover, trading volume in this decline was exceptionally high at 500% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 54.6% during the last week.
Current PriceTarget Research Rating
Corcept Therapeutics has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Corcept Therapeutics has a poor Appreciation Score of 23 but a very high Power Rating of 86, triggering the Neutral Value Trend Rating.
Be the first to comment